Eszopiclone
- Generic Name
- Eszopiclone
- Brand Names
- Lunesta
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17ClN6O3
- CAS Number
- 138729-47-2
- Unique Ingredient Identifier
- UZX80K71OE
- Background
Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.
One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.
- Indication
Eszopiclone is indicated for the treatment of insomnia.
- Associated Conditions
- Insomnia
Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping
- Conditions
- OSA - Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Flinders University
- Target Recruit Count
- 15
- Registration Number
- NCT06928766
- Locations
- 🇦🇺
Flinders University, Adelaide Institute for Sleep Health, Bedford Park, South Australia, Australia
Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder
- Conditions
- Chronic Insomnia Disorder
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Central South University
- Target Recruit Count
- 85
- Registration Number
- NCT06452953
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, China
Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA
- Conditions
- InsomniaObstructive Sleep Apnea
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06017921
- Locations
- 🇧🇷
Sleep Laboratory, Heart Institute, Pulmonary Division, Hospital das Clínicas da Universidade de São Paulo, Sao Paulo, Brazil
Endotypic Traits and Obstructive Sleep Apnea Surgery
- Conditions
- Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 150
- Registration Number
- NCT05953610
- Locations
- 🇺🇸
UCLA Santa Monica Medical Center, Santa Monica, California, United States
🇺🇸UCLA Westwood, Westwood, California, United States
Endotype-Targeted Therapy to Rescue OSA Patients Struggling with CPAP Adherence (TOP-CPAP)
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 50
- Registration Number
- NCT05951023
- Locations
- 🇺🇸
UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Laboratorios Andromaco S.A.
- Target Recruit Count
- 28
- Registration Number
- NCT05349396
- Locations
- 🇮🇳
Azidus Laboratories Ltd., Chennai, Tamil Nadu, India
Do Endotypes Predict Response and Sequelae in OSA Patients
- Conditions
- Sleep Apnea, ObstructiveSleepObstructive Sleep ApneaSleep ApneaSleep Disorder
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 200
- Registration Number
- NCT04875364
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
- Conditions
- OSAObstructive Sleep Apnea
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT04639193
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
🇺🇸UCSD Health - Pulmonary and Sleep Clinic, La Jolla, California, United States
Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD
- Conditions
- Complex Insomnia
- Interventions
- Behavioral: Brief behavioral therapy for insomnia
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 52
- Registration Number
- NCT03937713
- Locations
- 🇺🇸
VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York, United States
National Adaptive Trial for PTSD Related Insomnia
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 774
- Registration Number
- NCT03668041
- Locations
- 🇺🇸
Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States
🇺🇸Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States
🇺🇸Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.